Tyrosine Kinase Inhibitors Solidify Dominance in First and Second-Line GIST Treatment The cornerstone of systemic therapy for non-resectable or metastatic Gastrointestinal Stromal Tumors (GIST) is the application of Tyrosine Kinase Inhibitors (TKIs). These targeted agents, starting with Imatinib, have fundamentally altered the clinical prognosis for GIST patients, making them the largest and most valuable segment within the GIST treatment market. The high cost and long duration...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
